Yangbing Zhao
Adjunct Associate Professor of Pathology and Laboratory Medicine
Director, T Cell Engineering Lab, Abramson Family Cancer Research Institute, University of Pennsylvania
Department: Pathology and Laboratory Medicine
Contact information
3400 Civic Center Blvd
TRC 421, RM08-122
Philadelphia, pa 19104
TRC 421, RM08-122
Philadelphia, pa 19104
Office: 215-746-7618
Email:
yangbing@exchange.upenn.edu
yangbing@exchange.upenn.edu
Education:
BS, M.D (Medicine)
Third Military Medical University, Chongqing, China, 1985.
MSc (Surgery, Medicine)
Third Military Medical University, Chongqing, China, 1990.
Ph.D. (Surgery, Medicine)
Third Military Medical University, Chongqing, China, 1994.
Permanent linkBS, M.D (Medicine)
Third Military Medical University, Chongqing, China, 1985.
MSc (Surgery, Medicine)
Third Military Medical University, Chongqing, China, 1990.
Ph.D. (Surgery, Medicine)
Third Military Medical University, Chongqing, China, 1994.
Selected Publications
Barrett David M, Liu Xiaojun, Jiang Shuguang, June Carl H, Grupp Stephan A, Zhao Yangbing: Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. Human gene therapy 24(8): 717-27, Aug 2013.Marcela V. Maus, Andrew R. Haas, Gregory L. Beatty, Steven M. Albelda, Bruce L. Levine, Xiaojun Liu, Yangbing Zhao, Michael Kalos, and Carl H. June : T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans. Cancer Immunology Research. Glenn Dranoff (eds.). American Association for Cancer Research, 1: 26-31, July 2013.
Kunii Naoki, Zhao Yangbing, Jiang Shuguang, Liu Xiaojun, Scholler John, Balagopalan Lakshmi, Samelson Lawrence E, Milone Michael C, June Carl H: Enhanced function of redirected human T cells expressing linker for activation of T cells that is resistant to ubiquitylation. Human gene therapy 24(1): 27-37, Jan 2013.
Barrett David M, Zhao Yangbing, Liu Xiaojun, Jiang Shuguang, Carpenito Carmine, Kalos Michael, Carroll Richard G, June Carl H, Grupp Stephan A: Treatment of advanced leukemia in mice with mRNA engineered T cells. Human gene therapy 22(12): 1575-86, Dec 2011.
Zhu Yuyan, Obregon Demian, Hou Huayan, Giunta Brian, Ehrhart Jared, Fernandez Frank, Mori Takashi, Nikolic William, Zhao Yangbing, Morgan Dave, Town Terrence, Tan Jun: Mutant presenilin-1 deregulated peripheral immunity exacerbates Alzheimer-like pathology. Journal of cellular and molecular medicine 15(2): 327-38, Feb 2011.
Chinnasamy Dhanalakshmi, Yu Zhiya, Theoret Marc R, Zhao Yangbing, Shrimali Rajeev K, Morgan Richard A, Feldman Steven A, Restifo Nicholas P, Rosenberg Steven A: Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. The Journal of clinical investigation 120(11): 3953-68, Nov 2010.
Zhao Yangbing, Moon Edmund, Carpenito Carmine, Paulos Chrystal M, Liu Xiaojun, Brennan Andrea L, Chew Anne, Carroll Richard G, Scholler John, Levine Bruce L, Albelda Steven M, June Carl H: Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer research 70(22): 9053-61, Nov 2010.
Burns William R, Zhao Yangbing, Frankel Timothy L, Hinrichs Christian S, Zheng Zhili, Xu Hui, Feldman Steven A, Ferrone Soldano, Rosenberg Steven A, Morgan Richard A: A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer research 70(8): 3027-33, Apr 2010.
Zhao Yangbing, Wang Qiong J, Yang Shicheng, Kochenderfer James N, Zheng Zhili, Zhong Xiaosong, Sadelain Michel, Eshhar Zelig, Rosenberg Steven A, Morgan Richard A: A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. Journal of immunology (Baltimore, Md. : 1950) 183(9): 5563-74, Nov 2009.
Kochenderfer James N, Feldman Steven A, Zhao Yangbing, Xu Hui, Black Mary A, Morgan Richard A, Wilson Wyndham H, Rosenberg Steven A: Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. Journal of immunotherapy (Hagerstown, Md. : 1997) 32(7): 689-702, Sep 2009.